Pay in 4 interest-free payments of $5.70 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
Tirzepatide, a dual GIP/GLP-1 receptor agonist, has demonstrated greater efficacy in clinical trials, including the head-to-head SURMOUNT-5 trial comparing it to semaglutide 2.4 mg, potentially producing more substantial weight loss than traditional GLP-1 agonists alone
GLP-1 receptor agonists, such as semaglutide and liraglutide, are widely prescribed in the UK for type 2 diabetes and weight management
At the same time, its important to remember that results will vary depending on your baseline skin tone and metabolism
If diarrhoea persists, discuss nutritional monitoring with your healthcare provider
Do not exceed 4 capsules in a 24-hour period and do not use for more than 8 weeks
US$ 26.68
US$ 26.67
US$ 25.36
US$ 22.84
US$ 25.10
US$ 26.63
US$ 26.81
